Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction. BRS have had some issues in clinical trials not being able to match the performance of standard metallic drug eluting stents (DES) because of their thick stent struts. Newer generation BRS are in development with struts smaller than 100 micros, with will be closer to those of current generation metallic stents

 

News | Stents

August 21, 2019 — Increasing incidence of cardiovascular diseases worldwide is creating growth opportunities for the ...

Home August 21, 2019
Home
Blog | Cath Lab

There is a hype cycle surrounding new technologies in all industries, but medicine is unique because of its focus on ...

Home October 16, 2018
Home
Bioresorbable stents (BRS) in development presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward. #TCT #TCT2018
Feature | Stents Bioresorbable | Dave Fornell, Editor

Bioresorbable stent (BRS) technology is not dead, but the unbridled enthusiasm seen two years ago for the technology has ...

Home October 12, 2018
Home
News | Stents Bioresorbable

October 12, 2018 – Reva Medical presented four key data sets demonstrating the capabilities of the company’s Fantom bior ...

Home October 12, 2018
Home
Videos

A discussion with Professor Ian Meredith, MBBS, Ph.D., global chief medical officer and executive vice president, Boston ...

Home October 11, 2018
Home
Videos | TCT

DAIC Editor Dave Fornell takes a tour of some of the most innovative new cardiovascular technology he found on the expo ...

Home October 03, 2018
Home
News | Stents Bioresorbable

October 1, 2018 — New results from the RENASCENT studies presented at the Transcatheter Cardiovascular Therapeutics (TCT ...

Home October 01, 2018
Home
Videos | Stents Bioresorbable

Patrick Serruys, M.D., Ph.D., Imperial College London, explains where development of bioresorbable scaffolds stands in ...

Home August 06, 2018
Home
Amaranth's Fortitute bioresorbable stent scaffold. The company is developing smaller strut BRS.  Data presented at EuroPCR 2018
Feature | Stents Bioresorbable

June 19, 2018 – Amaranth Medical offered new details about its 85-micron Defiance bioresorbable scaffold (BRS) recently ...

Home June 19, 2018
Home
News | Stents Drug Eluting

May 31, 2018 – Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the ...

Home May 31, 2018
Home
News | Stents

January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling ...

Home January 25, 2018
Home
The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.
Feature | Stents Drug Eluting | Dave Fornell

There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or ...

Home January 17, 2018
Home
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.
Feature | Stents

November 8, 2017 – New results from the HARMONEE Japan/U.S. Registration Trial, reported by in a first report ...

Home November 08, 2017
Home
Videos | Stents Bioresorbable

A discussion with Ajay Kirtane, M.D., SM, director of the cardiac catheterization laboratories at New York-Presbyterian ...

Home November 07, 2017
Home
News | Stents Bioresorbable

October 31, 2017 – Thirty-day results from ABSORB IV, the largest randomized everolimus-eluting bioresorbable vascular ...

Home October 31, 2017
Home
Subscribe Now